Key facts
- This page summarizes Fred Schwarzer's Form 4 filing for IGM Biosciences, Inc. (IGMS).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 Jun 2024, 19:42.
Fred Schwarzer - 14 Jun 2024 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)
- Reporting relationship
- CEO AND PRESIDENT, Director
- Issuer ticker
- IGMS
- Reported as of
- 14 Jun 2024
- Net transaction value
- -$16,484
- SEC form
- 4
- Accepted by SEC
- 18 Jun 2024, 19:42:19 UTC
- Prior SEC filing
- 28 Mar 2024
- Next SEC filing
- 17 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Misbah Tahir, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Fred Schwarzer filed Form 4 for IGM Biosciences, Inc. (IGMS) on 18 Jun 2024.
Change
- Previous filing in this sequence was filed on 28 Mar 2024.
- Current net transaction value: -$16,484.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IGMS
transaction
Common Stock
Award
- Transaction value
- $15,060
- Shares
- +3,000
- Change %
- +1.2%
- Price
- $5.02
- Shares after
- 258,234
- Date
- 15 May 2024
- Ownership
- Direct
- Footnotes
- F1
IGMS
transaction
Common Stock
Sale
- Transaction value
- $31,544
- Shares
- -4,164
- Change %
- -1.6%
- Price
- $7.58
- Shares after
- 254,070
- Date
- 14 Jun 2024
- Ownership
- Direct
- Footnotes
- F2, F3
IGMS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 196,718
- Date
- 14 Jun 2024
- Ownership
- See footnote
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Footnote F2
These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
Footnote F3
This transaction was executed in multiple trades at prices ranging from $7.26 to $7.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Footnote F4
The shares are held by Fred M. Schwarzer & Deborah R. Schwarzer TTEES of the Schwarzer Family Trust U/A DTD 04/05/2018.